A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)
Phase 1
Recruiting
- Conditions
- Type 2 DiabetesTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- CTIS2023-507206-13-00
- Lead Sponsor
- Eli Lilly & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 888
Inclusion Criteria
Have Type 2 diabetes., Have been on stable diabetes treatment with metformin 90 days before study start through randomization., Have not lost or gained body weight for at least 90 days prior to baseline and agree to not start an intensive diet or exercise program during the study with the intent to lose body weight other than lifestyle and/or dietary measures for diabetes treatment.
Exclusion Criteria
Have Type 1 Diabetes, Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to baseline., Have had congestive heart failure., Have had heart attack, stroke or hospitalized for congestive heart failure
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method